Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY
Source: Streetwise Reports
October 25, 2017 (Investorideas.com Newswire) Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.
According to an Oct. 18 research note by Maxim analyst Anthony Vendetti, Viveve Medical Inc.'s (VIVE:NASDAQ) preliminary Q3/17 revenue of about $4.1 million was "up roughly 122% year over year, relatively in line with our estimate of $4.2M and above consensus of $3.7M."
Based on the quarter's results, Vendetti concluded, "We would continue to be buyers of Viveve after announcing preliminary Q3/17 revenue above the consensus estimate."
The analyst noted this women's health and wellness company "continues to build its installed base and make progress with additional international regulatory clearances."
For instance, in Q3/17, the company shipped 60 Geneveve systems, taking the number of installed machines to 365, and sold approximately 2,700 related consumables.
Additionally, Viveve "announced new regulatory clearances for the product in five additional countries," Vendetti said. Those are Bahrain, Kuwait, Qatar and Mexico for the treatment of vaginal laxity, and Taiwan for electrocoagulation to achieve hemostasis during surgery.
The biotech also continues to advance its clinical program, Vendetti indicated. It is preparing to submit an investigational device exemption request to the FDA so it may start its Viveve II clinical study. "Barring any regulatory hurdles, we expect the company to commence its Phase 3 trial by 2017E, with a readout of data projected for mid-2019," Vendetti wrote.
In the United States, the Geneveve device is "currently cleared for electrocoagulation and hemostasis," the analyst explained. "In our opinion, the possibility of gaining an expanded FDA approval for the improvement of female sexual function represents the major growth opportunity for the company."
Following Viveve's announcement of its Q3/17 revenue, Maxim Group changed its projected earnings estimate for the company from $15.1 million to $15.2 million but left all other estimates "relatively unchanged," Vendetti said.
Maxim has a Buy rating and $11 per share 12-month target price on Viveve, whose stock is now trading at around $5.53 per share.
The company's Q3/17 earnings call is scheduled for Wednesday, Nov. 8, 2017, at 5 p.m. ET.
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Viveve Medical. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Viveve Medical, a company mentioned in this article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.